亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

MAP Kinase Targeted Therapeutics

技术优势
High oral bioavailability Improved blood-brain barrier penetrance Increased metabolic stability Non-toxicity in rodent models Highly selective inhibition
详细技术说明
A validated novel compound and medicinal chemistry refinement for bioavailable small molecule inhibitors of protein kinases or protein kinase-mediated cellular stress response pathways.#therapeutics #cns
*Abstract

Northwestern researchers have identified and validated a novel compound with significant potential in the treatment of neurological diseases. In addition to the specific compound, this invention includes medicinal chemistry refinement which improves the bioavailability of small molecular inhibitors of protein kinases or protein kinase-medicated cellular stress response pathways. The investigators identified a small molecule p38α MAPK inhibitor which presents great therapy potential for CNS disorders in which proinflammatory cytokine overproduction is a component, such as Alzheimers (AD) and related indications, Parkinson's, multiple sclerosis, and traumatic brain injury. The CNS kinase inhibitor features a number of significant characteristics, making it an ideal candidate for CNS therapy. These include improved molecular properties having good oral bioavailability, blood-brain barrier penetrance, metabolic stability, and non-toxicity in in vivo rodent models. Furthermore, the inhibitor exhibited significant in vitro inhibition selectivity for only the p38α MAPK isoform. A platform for discovery and rapid refinement is established. An efficient synthetic scheme for the 069A lead p38α MAPK inhibitor and analogs has been developed. Current efforts focus on therapeutic index improvement in animal models and in vivo target validation.

*Inventors
Linda J. Van Eldik Daniel Martin Watterson*
*Publications
Munoz L, Ranaivo HR, Roy SM, Hu W, Craft JM, McNamara LK, Chico LW, Van Eldik LJ and Watterson DM (2007) A novel p38α MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Journal of Neuroinflammation. 4: 21.
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备